

COVID-19 Impact on Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/CCFBCAB34479EN.html>

Date: July 2020

Pages: 133

Price: US\$ 3,900.00 (Single User License)

ID: CCFBCAB34479EN

Abstracts

This report focuses on the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Pfizer

Novartis

Merck

AstraZeneca

Jhonson and Johnson

Eli Lilly

Sanofi

Bristol-Myers Squibb

Bayer

GSK

Teva Pharmaceutical

Shenzhen Salubris Pharmaceuticals

Sun Pharmaceutical

Mylan

Alembic Pharmaceuticals

Lupin

Aurobindo Pharma

Amneal Pharmaceuticals

Boehringer Ingelheim

Market segment by Type, the product can be split into

Valsartan

Irbesartan

Candesartan Cilexetil

Eprosartan

Irbesartan

Telmisartan

Losartan

Olmesartan Medoxomil

Allisartan isoproxil

Market segment by Application, split into

High Blood Pressure

Congestive Heart Failure

Left Ventricular Hypertrophy

Atherosclerosis

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players.

To present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist

development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Non-Peptide Drugs of Angiotensin II Receptor Antagonist are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue

1.4 Market Analysis by Type

1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Valsartan

1.4.3 Irbesartan

1.4.4 Candesartan Cilexetil

1.4.5 Eprosartan

1.4.6 Irbesartan

1.4.7 Telmisartan

1.4.8 Losartan

1.4.9 Olmesartan Medoxomil

1.4.10 Allisartan isoproxil

1.5 Market by Application

1.5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2020 VS 2026

1.5.2 High Blood Pressure

1.5.3 Congestive Heart Failure

1.5.4 Left Ventricular Hypertrophy

1.5.5 Atherosclerosis

1.5.6 Other

1.6 Coronavirus Disease 2019 (Covid-19): Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Impact

1.6.1 How the Covid-19 is Affecting the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry

1.6.1.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Non-Peptide Drugs of Angiotensin II Receptor Antagonist Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

- 1.6.3.1 Government Measures to Combat Covid-19 Impact
- 1.6.3.2 Proposal for Non-Peptide Drugs of Angiotensin II Receptor Antagonist
Players to Combat Covid-19 Impact
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Perspective (2015-2026)
- 2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Regions
 - 2.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions: 2015 VS 2020 VS 2026
 - 2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Share by Regions (2015-2020)
 - 2.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
 - 2.3.1 Market Top Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Challenges
 - 2.3.4 Porter's Five Forces Analysis
 - 2.3.5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Strategy
 - 2.3.6 Primary Interviews with Key Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Market Size
 - 3.1.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue (2015-2020)
 - 3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Players (2015-2020)
 - 3.1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Concentration Ratio

3.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2019

3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served

3.4 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service

3.5 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Type (2015-2020)

4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2021-2026)

5 NON-PEPTIDE DRUGS OF ANGIOTENSIN II RECEPTOR ANTAGONIST BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)

6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in North America (2019-2020)

6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)

6.4 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)

7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Europe (2019-2020)

7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)

7.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

8 CHINA

8.1 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)

8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in China (2019-2020)

8.3 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)

8.4 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)

9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Japan (2019-2020)

9.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)

9.4 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)

10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Size by Type (2015-2020)

10.4 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

11 INDIA

11.1 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)

11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in India (2019-2020)

11.3 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)

11.4 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)

12.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Central & South America (2019-2020)

12.3 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)

12.4 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Pfizer

13.1.1 Pfizer Company Details

13.1.2 Pfizer Business Overview and Its Total Revenue

13.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction

13.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020))

13.1.5 Pfizer Recent Development

13.2 Novartis

13.2.1 Novartis Company Details

13.2.2 Novartis Business Overview and Its Total Revenue

13.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction

- 13.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
- 13.2.5 Novartis Recent Development
- 13.3 Merck
 - 13.3.1 Merck Company Details
 - 13.3.2 Merck Business Overview and Its Total Revenue
 - 13.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 13.3.5 Merck Recent Development
- 13.4 AstraZeneca
 - 13.4.1 AstraZeneca Company Details
 - 13.4.2 AstraZeneca Business Overview and Its Total Revenue
 - 13.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 13.4.5 AstraZeneca Recent Development
- 13.5 Jhonson and Johnson
 - 13.5.1 Jhonson and Johnson Company Details
 - 13.5.2 Jhonson and Johnson Business Overview and Its Total Revenue
 - 13.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 13.5.5 Jhonson and Johnson Recent Development
- 13.6 Eli Lilly
 - 13.6.1 Eli Lilly Company Details
 - 13.6.2 Eli Lilly Business Overview and Its Total Revenue
 - 13.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 13.6.5 Eli Lilly Recent Development
- 13.7 Sanofi
 - 13.7.1 Sanofi Company Details
 - 13.7.2 Sanofi Business Overview and Its Total Revenue
 - 13.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

- 13.7.5 Sanofi Recent Development
- 13.8 Bristol-Myers Squibb
 - 13.8.1 Bristol-Myers Squibb Company Details
 - 13.8.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
 - 13.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 13.8.5 Bristol-Myers Squibb Recent Development
- 13.9 Bayer
 - 13.9.1 Bayer Company Details
 - 13.9.2 Bayer Business Overview and Its Total Revenue
 - 13.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 13.9.5 Bayer Recent Development
- 13.10 GSK
 - 13.10.1 GSK Company Details
 - 13.10.2 GSK Business Overview and Its Total Revenue
 - 13.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 13.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 13.10.5 GSK Recent Development
- 13.11 Teva Pharmaceutical
 - 10.11.1 Teva Pharmaceutical Company Details
 - 10.11.2 Teva Pharmaceutical Business Overview and Its Total Revenue
 - 10.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 10.11.4 Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 10.11.5 Teva Pharmaceutical Recent Development
- 13.12 Shenzhen Salubris Pharmaceuticals
 - 10.12.1 Shenzhen Salubris Pharmaceuticals Company Details
 - 10.12.2 Shenzhen Salubris Pharmaceuticals Business Overview and Its Total Revenue
 - 10.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 10.12.4 Shenzhen Salubris Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

- 10.12.5 Shenzhen Salubris Pharmaceuticals Recent Development
- 13.13 Sun Pharmaceutical
 - 10.13.1 Sun Pharmaceutical Company Details
 - 10.13.2 Sun Pharmaceutical Business Overview and Its Total Revenue
 - 10.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 10.13.4 Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 10.13.5 Sun Pharmaceutical Recent Development
- 13.14 Mylan
 - 10.14.1 Mylan Company Details
 - 10.14.2 Mylan Business Overview and Its Total Revenue
 - 10.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 10.14.4 Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 10.14.5 Mylan Recent Development
- 13.15 Alembic Pharmaceuticals
 - 10.15.1 Alembic Pharmaceuticals Company Details
 - 10.15.2 Alembic Pharmaceuticals Business Overview and Its Total Revenue
 - 10.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 10.15.4 Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 10.15.5 Alembic Pharmaceuticals Recent Development
- 13.16 Lupin
 - 10.16.1 Lupin Company Details
 - 10.16.2 Lupin Business Overview and Its Total Revenue
 - 10.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 10.16.4 Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 10.16.5 Lupin Recent Development
- 13.17 Aurobindo Pharma
 - 10.17.1 Aurobindo Pharma Company Details
 - 10.17.2 Aurobindo Pharma Business Overview and Its Total Revenue
 - 10.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
 - 10.17.4 Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
 - 10.17.5 Aurobindo Pharma Recent Development

13.18 Amneal Pharmaceuticals

10.18.1 Amneal Pharmaceuticals Company Details

10.18.2 Amneal Pharmaceuticals Business Overview and Its Total Revenue

10.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor

Antagonist Introduction

10.18.4 Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

10.18.5 Amneal Pharmaceuticals Recent Development

13.19 Boehringer Ingelheim

10.19.1 Boehringer Ingelheim Company Details

10.19.2 Boehringer Ingelheim Business Overview and Its Total Revenue

10.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor

Antagonist Introduction

10.19.4 Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

10.19.5 Boehringer Ingelheim Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Market Segments

Table 2. Key Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue

Table 3. Ranking of Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Valsartan

Table 6. Key Players of Irbesartan

Table 7. Key Players of Candesartan Cilexetil

Table 8. Key Players of Eprosartan

Table 9. Key Players of Irbesartan

Table 10. Key Players of Telmisartan

Table 11. Key Players of losartan

Table 12. Key Players of Olmesartan Medoxomil

Table 13. Key Players of Allisartan isoproxil

Table 14. COVID-19 Impact Global Market: (Four Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast Scenarios)

Table 15. Opportunities and Trends for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players in the COVID-19 Landscape

Table 16. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 17. Key Regions/Countries Measures against Covid-19 Impact

Table 18. Proposal for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players to Combat Covid-19 Impact

Table 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (US\$ Million): 2020 VS 2026

Table 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (2015-2020) (US\$ Million)

Table 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2015-2020)

Table 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 24. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2021-2026)

Table 25. Market Top Trends

Table 26. Key Drivers: Impact Analysis

Table 27. Key Challenges

Table 28. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Strategy

Table 29. Main Points Interviewed from Key Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players

Table 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Players (2015-2020) (Million US\$)

Table 31. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players (2015-2020)

Table 32. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2019)

Table 33. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Players Market Concentration Ratio (CR5 and HHI)

Table 34. Key Players Headquarters and Area Served

Table 35. Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service

Table 36. Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Table 37. Mergers & Acquisitions, Expansion Plans

Table 38. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 39. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Type (2015-2020)

Table 40. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2021-2026)

Table 41. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Application (2015-2020)

Table 42. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 43. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Application (2021-2026)

Table 44. North America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US\$)

Table 45. North America Key Players Non-Peptide Drugs of Angiotensin II Receptor

Antagonist Market Share (2019-2020)

Table 46. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 47. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)

Table 48. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 49. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)

Table 50. Europe Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US\$)

Table 51. Europe Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)

Table 52. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 53. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)

Table 54. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 55. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)

Table 56. China Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US\$)

Table 57. China Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)

Table 58. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 59. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)

Table 60. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 61. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)

Table 62. Japan Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US\$)

Table 63. Japan Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)

Table 64. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 65. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)

Table 66. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 67. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)

Table 68. Southeast Asia Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US\$)

Table 69. Southeast Asia Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)

Table 70. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 71. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)

Table 72. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 73. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)

Table 74. India Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US\$)

Table 75. India Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)

Table 76. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 77. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)

Table 78. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 79. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)

Table 80. Central & South America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US\$)

Table 81. Central & South America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)

Table 82. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US\$)

Table 83. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)

Table 84. Central & South America Non-Peptide Drugs of Angiotensin II Receptor

Antagonist Market Size by Application (2015-2020) (Million US\$)

Table 85. Central & South America Non-Peptide Drugs of Angiotensin II Receptor

Antagonist Market Share by Application (2015-2020)

Table 86. Pfizer Company Details

Table 87. Pfizer Business Overview

Table 88. Pfizer Product

Table 89. Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 90. Pfizer Recent Development

Table 91. Novartis Company Details

Table 92. Novartis Business Overview

Table 93. Novartis Product

Table 94. Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 95. Novartis Recent Development

Table 96. Merck Company Details

Table 97. Merck Business Overview

Table 98. Merck Product

Table 99. Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 100. Merck Recent Development

Table 101. AstraZeneca Company Details

Table 102. AstraZeneca Business Overview

Table 103. AstraZeneca Product

Table 104. AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 105. AstraZeneca Recent Development

Table 106. Jhonson and Johnson Company Details

Table 107. Jhonson and Johnson Business Overview

Table 108. Jhonson and Johnson Product

Table 109. Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 110. Jhonson and Johnson Recent Development

Table 111. Eli Lilly Company Details

Table 112. Eli Lilly Business Overview

Table 113. Eli Lilly Product

Table 114. Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 115. Eli Lilly Recent Development

- Table 116. Sanofi Company Details
- Table 117. Sanofi Business Overview
- Table 118. Sanofi Product
- Table 119. Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)
- Table 120. Sanofi Recent Development
- Table 121. Bristol-Myers Squibb Business Overview
- Table 122. Bristol-Myers Squibb Product
- Table 123. Bristol-Myers Squibb Company Details
- Table 124. Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)
- Table 125. Bristol-Myers Squibb Recent Development
- Table 126. Bayer Company Details
- Table 127. Bayer Business Overview
- Table 128. Bayer Product
- Table 129. Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)
- Table 130. Bayer Recent Development
- Table 131. GSK Company Details
- Table 132. GSK Business Overview
- Table 133. GSK Product
- Table 134. GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)
- Table 135. GSK Recent Development
- Table 136. Teva Pharmaceutical Company Details
- Table 137. Teva Pharmaceutical Business Overview
- Table 138. Teva Pharmaceutical Product
- Table 139. Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)
- Table 140. Teva Pharmaceutical Recent Development
- Table 141. Shenzhen Salubris Pharmaceuticals Company Details
- Table 142. Shenzhen Salubris Pharmaceuticals Business Overview
- Table 143. Shenzhen Salubris Pharmaceuticals Product
- Table 144. Shenzhen Salubris Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)
- Table 145. Shenzhen Salubris Pharmaceuticals Recent Development
- Table 146. Sun Pharmaceutical Company Details
- Table 147. Sun Pharmaceutical Business Overview
- Table 148. Sun Pharmaceutical Product

Table 149. Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 150. Sun Pharmaceutical Recent Development

Table 151. Mylan Company Details

Table 152. Mylan Business Overview

Table 153. Mylan Product

Table 154. Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 155. Mylan Recent Development

Table 156. Alembic Pharmaceuticals Company Details

Table 157. Alembic Pharmaceuticals Business Overview

Table 158. Alembic Pharmaceuticals Product

Table 159. Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 160. Alembic Pharmaceuticals Recent Development

Table 161. Lupin Company Details

Table 162. Lupin Business Overview

Table 163. Lupin Product

Table 164. Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 165. Lupin Recent Development

Table 166. Aurobindo Pharma Company Details

Table 167. Aurobindo Pharma Business Overview

Table 168. Aurobindo Pharma Product

Table 169. Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 170. Aurobindo Pharma Recent Development

Table 171. Amneal Pharmaceuticals Company Details

Table 172. Amneal Pharmaceuticals Business Overview

Table 173. Amneal Pharmaceuticals Product

Table 174. Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 175. Amneal Pharmaceuticals Recent Development

Table 176. Boehringer Ingelheim Company Details

Table 177. Boehringer Ingelheim Business Overview

Table 178. Boehringer Ingelheim Product

Table 179. Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US\$)

Table 180. Boehringer Ingelheim Recent Development

Table 181. Research Programs/Design for This Report

Table 182. Key Data Information from Secondary Sources

Table 183. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type: 2020 VS 2026
- Figure 2. Valsartan Features
- Figure 3. Irbesartan Features
- Figure 4. Candesartan Cilexetil Features
- Figure 5. Eprosartan Features
- Figure 6. Irbesartan Features
- Figure 7. Telmisartan Features
- Figure 8. losartan Features
- Figure 9. Olmesartan Medoxomil Features
- Figure 10. Allisartan isoproxil Features
- Figure 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2020 VS 2026
- Figure 12. High Blood Pressure Case Studies
- Figure 13. Congestive Heart Failure Case Studies
- Figure 14. Left Ventricular Hypertrophy Case Studies
- Figure 15. Atherosclerosis Case Studies
- Figure 16. Other Case Studies
- Figure 17. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Report Years Considered
- Figure 18. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions: 2020 VS 2026
- Figure 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2021-2026)
- Figure 21. Porter's Five Forces Analysis
- Figure 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players in 2019
- Figure 23. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2019)
- Figure 24. The Top 10 and 5 Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2019
- Figure 25. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist

Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US\$)

Figure 27. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US\$)

Figure 28. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US\$)

Figure 29. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US\$)

Figure 30. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US\$)

Figure 31. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US\$)

Figure 32. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Pfizer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 34. Novartis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Novartis Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 36. Merck Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Merck Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 38. AstraZeneca Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. AstraZeneca Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 40. Jhonson and Johnson Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Jhonson and Johnson Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 42. Eli Lilly Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Eli Lilly Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 44. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. Sanofi Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 46. Bristol-Myers Squibb Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 48. Bayer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Bayer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 50. GSK Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. GSK Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 52. Teva Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. Teva Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 54. Shenzhen Salubris Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. Shenzhen Salubris Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 56. Sun Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 57. Sun Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 58. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 59. Mylan Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 60. Alembic Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 61. Alembic Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 62. Lupin Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 63. Lupin Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 64. Aurobindo Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 65. Aurobindo Pharma Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 66. Amneal Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 67. Amneal Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 68. Boehringer Ingelheim Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 69. Boehringer Ingelheim Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/CCFBCAB34479EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCFBCAB34479EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

